Electra Therapeutics Announces ELA026 Granted EMA Orphan Drug Designation for the Treatment of Secondary Hemophagocytic Lymphohistiocytosis (sHLH)

ELA026 has demonstrated promising potential to address the high unmet need for patients with sHLH, a rare, life-threatening hyperinflammatory disease with limited treatment options SOUTH SAN FRANCISCO, CA, August 4, 2025 – Electra Therapeutics, a clinical stage biotechnology company pioneering